Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy
Authors:
- Luciana Marangoni-IgleciasLMLuciana Marangoni-Iglecias
- Susana Rojo-TolosaSRSusana Rojo-Tolosa
- Noelia Márquez-PeteNMNoelia Márquez-Pete
- Yasmín CuraYCYasmín Cura
- Noelia Moreno-ToroNMNoelia Moreno-Toro
- Cristina Membrive-JiménezCristina Membrive-Jiménez
- Almudena Sánchez-MartinASAlmudena Sánchez-Martin
- Cristina Pérez-RamírezCPCristina Pérez-Ramírez
- Alberto Jiménez-MoralesAJAlberto Jiménez-Morales
Open Access
- 13 August 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8797
Abstract
Cancer is the leading cause of disease-related death among children. Vincristine (VCR), a key component of childhood cancer treatment protocols, is associated with the risk of peripheral neuropathy (PN), a condition that may be reversible upon drug discontinuation but can also leave lasting sequelae. Single nucleotide polymorphism (SNP) in genes involved in VCR pharmacokinetics and pharmacodynamics have been investigated in relation to an increased risk of PN. However, the results of these studies have been inconsistent. A retrospective cohort study was conducted to investigate the potential association of drug transporter genes from the ATP-binding cassette (ABC) family and the centrosomal protein 72 (CEP72) gene with the development of PN in 88 Caucasian children diagnosed with cancer and treated with VCR. Genotyping was performed using real-time PCR techniques for the following SNPs: ABCB1 rs1128503, ABCC1 rs246240, ABCC2 rs717620, and CEP72 rs924607. The results indicated that age at diagnosis (OR = 1.33; 95% CI = 1.07–1.75) and the ABCC1 rs246240 G allele (OR = 12.48; 95% CI = 2.26–100.42) were associated with vincristine-induced peripheral neuropathy (VIPN). No association was found between this toxicity and CEP72 rs924607. Our study provides insights that may contribute to optimizing childhood cancer therapy in the future by predicting the risk of VIPNKeywords
Funding Information
- Instituto de Salud Carlos III (PT13/0010/0039)
This publication has 43 references indexed in Scilit:
- Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and TreatmentOncology and Therapy, 2021
- Childhood cancer: Survival, treatment modalities, late effects and improvements over timeCancer Epidemiology, 2021
- Genome wide association studies for treatment‐related adverse effects of pediatric acute lymphoblastic leukemiaWIREs Mechanisms of Disease, 2020
- Carboplatin and vincristine neurotoxicity in the treatment of pediatric low‐grade gliomasPediatric Blood & Cancer, 2018
- Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy GenesClinical Pharmacology & Therapeutics, 2018
- PharmGKB: A worldwide resource for pharmacogenomic informationWIREs Mechanisms of Disease, 2018
- Vincristine-induced peripheral neuropathy in children with cancer: A systematic reviewCritical Reviews in Oncology/Hematology, 2017
- An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic LeukemiaClinical Pharmacology & Therapeutics, 2016
- Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic LeukemiaJAMA, 2015
- Chemotherapy-Related Neuropathic Symptoms and Functional Impairment in Adult Survivors of Extracranial Solid Tumors of Childhood: Results From the St. Jude Lifetime Cohort StudyArchives of Physical Medicine and Rehabilitation, 2013